The cardiovascular safety of methylphenidate
- PMID: 27245078
- PMCID: PMC4887615
- DOI: 10.1136/bmj.i2874
The cardiovascular safety of methylphenidate
Abstract
What to make of studies that agree to disagree
Conflict of interest statement
Competing interests: I have read and understood the BMJ Group policy on declaration of interests and declare the following interests: none.
Comment on
- Research, doi: 10.1136/bmj.i2550 doi: 10.1136/bmj.i2550
References
-
- Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 2012;130:23-31. 10.1542/peds.2011-2879 pmid:22711728. - DOI - PubMed
-
- Munk K, Gormsen L, Kim WY, Andersen NH. Cardiac Arrest following a Myocardial Infarction in a Child Treated with Methylphenidate. Case Rep Pediatr 2015;2015:905097 10.1155/2015/905097 pmid:26221559. - DOI - PMC - PubMed
-
- Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. CNS Drugs 2013;27:15-30. 10.1007/s40263-012-0019-9 pmid:23160939. - DOI - PubMed
-
- Winterstein AG, Gerhard T, Kubilis P, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012;345:e4627 10.1136/bmj.e4627 pmid:22809800. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources